Genera / prostatae / prostate, hormone-quod-Lorem sheet,
Index
Therapy pro hormone prostatae Cancer
Quis hormones in masculum sexus?
Hormones substantiae corporis munus a glandulis eget significationibus. Et afficit ad actiones ex variis locis in cellulis et textuum in corpus, saepe reaching sua proposita per iter faciebat per bloodstream.
Androgens (masculum sexus Hormones) sint in genere hormones quod control progressio sunt masculus et in tutela Domini sunt. Testosterone et dihydrotestosterone (DHT) sunt maxime abundat androgens apud homines. Producatur pene testosterone incutiunt; productum moles parva est a adrenal glandulis. Praeterea, aliqui prostate cancer cellulis, potuerimus ad testosterone, a turpis (I).
Quomodo hormones incitare incrementum prostate cancer?
Androgens non requiritur normalis incrementum et ad munus in in prostate, masculum generatiua ratio est glandula in hoc adjuvat planto decisionem seminis. Androgens prostate cancer est etiam necessarium ad crescere. Androgens promovere incrementum normalis et prostate et carcinomatum cellulis per quod androgen receptor binding, ut activum et, dapibus a amet plena, prostata in (II). Cum activated: androgen receptor quod ex propria expressio stimulat, quae causa prostate genes in cellulis crescere (III).
In mane progressionem, prostate cancer opus est relative altum campester crescere usque ad androgens. Tales prostate cancer dicuntur idem rursus sensitivo, androgen dependens aut androgen treatments sensitivo, quia non campester minuatur aut androgen obstructionum androgen sua actione potest inhibere incrementum.
Prostate surgery aut cancer medicinae tractata est, quod successu temporis in idem rursus androgens obstructionum (vel castrare) repugnant, quae modo ut permanere possint germinare et cum in corpore sunt maxime humilis gradus androgen et egredientem. Et huiusmodi similitudines anorum sunt etiam praeterita hormone vocavit repugnans, androgen sui iuris, vel hormone durum; tamen haec verba sunt, quae raro usus est autem ani aurei facti sunt, quia curatione feminam inire repugnant, vel β respondeant usque ad recentiora antiandrogen medicaménta utíliter.
Quibus generibus usus sunt pro hormone Lorem prostate cancer?
Lorem hormone productionem et usu ad prostate cancer potest angustos in androgens de (IV). Currently praesto treatments potest facere quae pluribus modis solvitur:
- Reducing androgen productio per ij corpori impertiunt,
- Androgens claudebant actio totius corporis
- Androgen impedimentum productio (componendo) totius corporis
Treatments ut redigo androgen productio hormone maxime plerumque adsuesco assuesco per testes conspectiores evadere therapies pro prostate cancer et primam rationem, quae maxima cum prostate cancer accipere Lorem hormone. Lorem haec species hormone (also called androgen Lorem privatio, aut ADT) includit:
- Orchiectomy, amovere vel chirurgicam procedendi ad utrumque ablatisque testiculis est. Testosterone campester of remotionem testes nihilominus in sanguinem minuere et a XCV% ad XC (V). Hoc genus treatment, quae manu redditur, dicitur curatione feminam inire, est permanens et irrevocabilis. A genus orchiectomy dicitur subcapsular orchiectomy TEXTUS tantum removet generans in testibus androgens, quam totum testiculum abscidit.
- Medicamenta quæ vocatur Luteinizing hormone-Hormon (LHRH) agonists, et ne secretionem in hormone vocavit Luteinizing hormone. LHRH agonists quae dicantur LHRH analogs es servo synthetica quae in constitutione similis LHRH receptor LHRH ad glandulam pituitariam ligant. (Quae etiam est LHRH gonadotropin Hormon, aut GnRH, et quoque quae vocatur LHRH agonists GnRH agonists.)
Communiter autem gradus androgen corporis humiliat LHRH excitat ad glandulam pituitariam Luteinizing hormone quae vicissim concitat androgens fructibus testibus. LHRH agonists velut a corpore suo LHRH, ab initio summam Luteinizing hormone productionem. Tamen, princeps gradus ex praesentia continua LHRH agonists actu causat prohibere ad glandulam pituitariam producendo Luteinizing hormone et quasi effectus sunt testes producere androgens cultum excitantur.
Cum dicitur treatment medical LHRH agonist curatione feminam inire, vel quod idem rursus eget mauris et implerem utitur idem quod idem rursus quae manu redditur (orchiechtomy). Sed, dissimilis orchiectomy, ad productionem effectus haec medicinae sunt in androgen convertitur. Cum treatment intercluditur: androgen plerumque productio resumit.
LHRH agonists sunt a infunduntur aut praecepta insinuantur aut sub cute. LHRH agonists quattuor facies autem probatus est prostate cancer in Civitatibus Foederatis Americae, leuprolide, goserelin, triptorelin et histrelin.
Cum aegris LHRH agonist accipere in propter primum, ut ibi percipiant phaenomenon vocatur "testosterone flare." Et hoc contingit ex hoc quod temporalis incremento in testosterone campester LHRH agonists pituitam glandem ad occultant extra breviter causa est ante asilo subierunt, eiusdem release Luteinizing hormone. Et excandescunt Volume symptoms ut peior fieri (exempli gratia, os dolor, vesicae laxi impediendam vel ureteris et medulla spinalis compressionem), qui potest esse quaestio maxime homines in provectus prostate cancer. Augmentum hormone testosterone est plerumque prae dare aliud genus Lorem Lorem una cum dicitur antiandrogen LHRH agonist ad primas hebdomadas curatio.
- Medicamenta dicitur LHRH antagonistis suscipiunt, quae sunt alia forma medicorum curatione feminam inire. LHRH antagonistis suscipiunt (also called GnRH antagonistis suscipiunt) LHRH ne ex receptorum suum in glandulam pituitariam binding. Hoc facit ut Luteinizing hormone secretio, quae consistit in producendo ex androgens ablatisque testiculis est. Secus LHRH agonists, LHRH committuntur, animum non faciam de testosterone flare.
Unum LHRH Libano, degarelix, provectus est currently probatus est tractare prostate cancer in Civitatibus Foederatis Americae. Factum est a iniectio.
- Estrogens (promote feminam sexus Hormones qui habet). Et cum estrogens quae potest inhibere productio androgen in ablatisque testiculis est, non raro usus est hodie a parte illorum ob curatio prostate cancer effectus.
Treatments angustos actiones, quae in corpore androgens (also called antiandrogen therapies) typice usus est, cum impii extinguetur nec opus ADT. Treatments talis includit:
- Androgen receptor blockers (also called androgen receptor antagonistis suscipiunt) venenum ut certet Amyntas androgens quae est in androgen receptor binding. Per competing quia in androgen receptor binding, haec treatments ad redigendum facultatem ad promovere androgens ab prostate cancer cellam augmentum.
Quia non angustos androgen receptor blockers androgen productionem, sunt raro usus est in facies suas a prostate cancer. Instead, quae sunt usus in combinatione cum ADT (vel orchiectomy nec LHRH agonist). Respectu usus androgen receptor obstructorem orchiectomy aut coniuncta est LHRH Dorsi androgen obsidio obsidium omni androgen aut androgen totum omisit.
Androgen receptor blockers, qui sunt in Civitatibus Foederatis Americae probatus est prostate cancer facies includit flutamide, enzalutamide, apalutamide, bicalutamide et nilutamide. Ut absorbeatur pilulas dantur.
Treatments ut angustos androgens productio est per totum corpus includit:
- Androgen inhibitors exstant, quae sunt in nube, ne androgens productionem de a adrenal glandulis et prostate cancer cellulis, tum in testes irruere. Neque obstat quo minus idem rursus medicinae vel chirurgicam adrenal glandulis et prostate cancer cellulis a producendo androgens. Quamquam haec copia androgens in parvis cellulis producere, possunt aliqui non sufficere ad opitulandum quod incrementum a prostate cancer.
Androgen testosterone campester summam inhibitors deterius corpus hominis notas prae aliis magis placet. Haec medicinae angustos enzyme vocavit CYP17 a Inhibito testosterone productionem. Rectum est, quod in testium, glandula et prostatae tumore textuum corporis requiritur ad testosterone a turpis.
Tres sunt probatus inhibitors summam androgen in Civitatibus Foederatis Americae, abiraterone acetate, ketoconazole et aminoglutethimide. Omnia dentur pilulas devorabitur.
Valium tractare respectu Abiraterone acetate probatus metastatic metastatic castrati summum periculum cancer repugnans castrati minusculasque prostatae prostatae turpis. Prior est ex approbatione abiraterone enzalutamide et duo signa medicinae probatus est aliud quam uti nunc sunt, prostate cancer-off-Pittacium ketoconazole et aminoglutethimide treatments pro quod secundum idem rursus acie-prostate cancer repugnans.
Quid facies solebat hormone curatio prostate cancer?
Lorem hormone potest esse in pluribus modi tractare prostate cancer, comprehendo:
Early-stage prostate cancer with an intermediate or high risk of recurrence. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence often receive hormone therapy before, during, and/or after radiation therapy, or they may receive hormone therapy after prostatectomy (surgery to remove the prostate gland) (6). Factors that are used to determine the risk of prostate cancer recurrence include the tumor's grade (as measured by the Gleason score), the extent to which the tumor has spread into surrounding tissue, and whether tumor cells are found in nearby lymph nodes during surgery.
The length of treatment with hormone therapy for early-stage prostate cancer depends on a man’s risk of recurrence. For men with intermediate-risk prostate cancer, hormone therapy is generally given for 6 months; for men with high-risk disease it is generally given for 18–24 months.
Men who have hormone therapy after prostatectomy live longer without having a recurrence than men who have prostatectomy alone, but they do not live longer overall (6). Men who have hormone therapy after external beam radiation therapy for intermediate- or high-risk prostate cancer live longer, both overall and without having a recurrence, than men who are treated with radiation therapy alone (6, 7). Men who receive hormone therapy in combination with radiation therapy also live longer overall than men who receive radiation therapy alone (8). However, the optimal timing and duration of ADT, before and after radiation therapy, has not been established (9, 10).
The use of hormone therapy (alone or in combination with chemotherapy) before prostatectomy has not been shown to prolong survival and is not a standard treatment. More intensive androgen blockade prior to prostatectomy is being studied in clinical trials.
Relapsed/recurrent prostate cancer. Hormone therapy used alone is the standard treatment for men who have a prostate cancer recurrence as documented by CT, MRI, or bone scan after treatment with radiation therapy or prostatectomy. therapy is sometimes recommended for men who have a "biochemical" recurrence—a rise in prostate-specific antigen (PSA) level following primary local treatment with surgery or radiation—especially if the PSA level doubles in fewer than 3 months and the cancer has not spread.
A randomized clinical trial among men with biochemical recurrence after prostatectomy found that men who had antiandrogen therapy plus radiation treatment were less likely to develop metastases or die from prostate cancer or overall than men who had placebo plus radiation (11). However, patients with lower PSA values did not appear to benefit from the addition of hormone therapy to radiation. Another recent clinical trial showed that for men with rising PSA levels after primary local therapy who were at high risk of metastasis but had no evidence of metastatic disease, adding chemotherapy with docetaxel to ADT was not superior to ADT in terms of several measures of survival (12).
Advanced or metastatic prostate cancer. Hormone therapy used alone is the standard treatment for men who are found to have metastatic disease (i.e., disease that has spread to other parts of the body) when their prostate cancer is first diagnosed (13). Clinical trials have shown that such men survive longer when treated with ADT plus abiraterone/prednisone, enzalutamide, or apalutamide than when treated with ADT alone (14–17). However, because hormone therapy can have substantial side effects, some men prefer not to take hormone therapy until symptoms develop.
Early results of an NCI-sponsored trial that was conducted by two cancer cooperative groups—the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN)—suggested that men with hormone-sensitive metastatic prostate cancer who receive the chemotherapy drug docetaxel at the start of standard hormone therapy live longer than men who receive hormone therapy alone. Men with the most extensive metastatic disease appeared to benefit the most from the early addition of docetaxel. These findings were recently confirmed with longer follow-up (18).
Palliation docebo. Lorem hormone aliquando usus est, quia solus palliation vel praeventioni mali sive loci signa sunt in homines, qui non sunt localized prostate cancer radialis Lorem candidati aut surgery (XIX). Hos includit limitata vitae expectationem cum his, qui provectus locis in secretiori parte natium: et / aut alia gravis valetudo conditionibus, cum illis.
Admitte comment refrigerium auto-